Compare HKPD & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKPD | TNON |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Hong Kong | United States |
| Employees | 27 | 27 |
| Industry | Other Pharmaceuticals | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.6M |
| IPO Year | N/A | N/A |
| Metric | HKPD | TNON |
|---|---|---|
| Price | $0.52 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 27.8K | ★ 137.7K |
| Earning Date | 08-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $65.95 |
| Revenue Next Year | N/A | $50.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.64 |
| 52 Week High | $2.74 | $2.48 |
| Indicator | HKPD | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 46.42 |
| Support Level | $0.37 | $0.72 |
| Resistance Level | $0.70 | $0.91 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 45.45 | 37.60 |
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.